Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

July 31, 2005

Study Completion Date

October 31, 2014

Conditions
Breast Cancer
Interventions
DRUG

Exemestane

25mg/day until progression disease

DRUG

Anastrozole

1mg/day until progression disease

Trial Locations (13)

20012

Onkologikoa, Donostia / San Sebastian

20014

Hospital Donostia, Donostia / San Sebastian

28040

Hospital Clínico Universitario San Carlos, Madrid

46009

Instituto Valenciano de Oncología (IVO), Valencia

Unknown

Germans Trias i Pujol, Badalona

Clínico Universitario A Coruña (CHUAC), A Coruña

H Comarcal de Barbastro, Barbastro

H Puerto de Sagunto, Sagunto

Puerta de Hierro, Madrid

Ruber Internacional, Madrid

H Sant Camil, Tarragona

Clínico Lozano Blesa, Zaragoza

H Universitario Miguel Servet, Zaragoza

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Spanish Breast Cancer Research Group

OTHER